Position in NVS
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$1,989,090
-$71,660 QoQ
Shares Held
12,692
-5.9% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#434
of 1,603 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Sterling Capital Management LLC holds $175,509,703 across 14 Drug Manufacturers - General names. NVS ranks #9 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
53,980 | $64,745,235 | |
| 2 | ABBV |
AbbVie Inc.
|
178,425 | $44,898,866 | |
| 3 | AMGN |
Amgen Inc
|
58,377 | $21,139,478 | |
| 4 | MRK |
Merck & Co., Inc.
|
108,307 | $13,917,449 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
220,345 | $12,696,278 | |
| 6 | JNJ |
Johnson & Johnson
|
30,107 | $7,646,273 | |
| 7 | AZN |
Astrazeneca PLC
|
14,562 | $2,761,245 | |
| 8 | NVO |
Novo Nordisk A S
|
49,472 | $2,371,687 |
All Filings in NVS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,989,090 | 12,692 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $2,060,750 | 13,491 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $1,860,142 | 13,492 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,829,215 | 14,264 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,392,099 | 11,504 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $1,158,611 | 10,393 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $1,153,318 | 11,852 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $1,519,414 | 13,210 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||